# Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

> **NCT07230613** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 50 (estimated)

## Conditions studied

- Cutaneous Melanoma, Stage III
- Mucosal Melanoma

## Interventions

- **DRUG:** Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- **DRUG:** Nivolumab (OpdivoTM, 40 mg/4mL solution)

## Key facts

- **NCT ID:** NCT07230613
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2027-12
- **Final completion:** 2033-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230613, "Neo-adjuvant Immunotherapy in Patients With Localized Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07230613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*